Kuopio Research Center of Geriatric Care and School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
Kuopio Research Center of Geriatric Care and School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
J Am Med Dir Assoc. 2023 Sep;24(9):1290-1296.e4. doi: 10.1016/j.jamda.2023.04.004. Epub 2023 May 20.
The use of antipsychotics in persons with Parkinson's disease (PD) is common, although their use may aggravate the symptoms of PD. Clozapine and quetiapine are the only antipsychotics recommended in PD treatment guidelines. Information on factors associated with initiation of antipsychotics is needed. We investigated whether recent hospitalization is associated with initiation of antipsychotics in persons with PD, and whether discharge diagnoses differ between those who had antipsychotics initiated and those who did not.
Nested case-control study in the nationwide register-based Finnish Study on Parkinson's disease (FINPARK).
The FINPARK study includes 22,189 persons who received an incident, clinically verified PD diagnosed during 1996-2015 and were community-dwelling at the time of diagnosis. The cases were 5088 persons who had antipsychotics initiated after PD diagnosis, identified with 1-year washout. The controls were 5088 age-, sex-, and time from PD diagnosis-matched persons who did not use antipsychotics on the matching date (antipsychotic purchase date). Recent hospitalization was defined as discharge in the 2-week period preceding the matching date.
Associations were investigated with conditional logistic regression.
Quetiapine was the most commonly initiated antipsychotic (72.0% of cases), followed by risperidone (15.0%). Clozapine was initiated rarely (1.1%). Recent hospitalization associated strongly with antipsychotic initiation [61.2% of cases and 14.9% of controls, odds ratio (OR) 9.42, 95% CI 8.33-10.65], and longer hospitalizations were more common among cases. PD was the most common discharge diagnosis category (51.2% of hospitalized cases and 33.0% controls), followed by mental and behavioral disorders (9.3%) and dementia (9.0%) among cases. Antidementia and other psychotropic medication use were more common among cases.
These results suggest that antipsychotics were initiated because of neuropsychiatric symptoms or aggravation of those symptoms. Antipsychotics should be prescribed after careful consideration to avoid adverse effects in persons with Parkinson's disease.
在帕金森病(PD)患者中使用抗精神病药物很常见,尽管它们的使用可能会加重 PD 的症状。氯氮平和喹硫平是 PD 治疗指南中唯一推荐的抗精神病药物。需要了解与开始使用抗精神病药物相关的因素。我们调查了最近的住院是否与 PD 患者开始使用抗精神病药物有关,以及在开始使用和未使用抗精神病药物的患者之间,出院诊断是否存在差异。
在全国基于登记的芬兰帕金森病研究(FINPARK)中进行嵌套病例对照研究。
FINPARK 研究包括 22189 名在 1996-2015 年期间接受过临床确诊的、首发、临床确诊的 PD 且在诊断时居住在社区的患者。病例组为 5088 名在 PD 诊断后开始使用抗精神病药物的患者,采用 1 年洗脱期。对照组为 5088 名年龄、性别和 PD 诊断后时间匹配的患者,他们在匹配日期(抗精神病药物购买日期)没有使用抗精神病药物。最近的住院定义为在匹配日期前 2 周内出院。
使用条件逻辑回归调查关联。
喹硫平是最常用的起始抗精神病药物(72.0%的病例),其次是利培酮(15.0%)。很少开始使用氯氮平(1.1%)。最近的住院与抗精神病药物的起始强烈相关[61.2%的病例和 14.9%的对照组,比值比(OR)9.42,95%可信区间(CI)8.33-10.65],并且住院时间较长的病例更为常见。PD 是最常见的出院诊断类别(51.2%的住院病例和 33.0%的对照组),其次是精神和行为障碍(9.3%)和痴呆(9.0%)。病例组中抗痴呆和其他精神药物的使用更为常见。
这些结果表明,抗精神病药物是因为神经精神症状或这些症状的加重而开始使用的。在帕金森病患者中使用抗精神病药物应慎重考虑,以避免不良反应。